JP2018528162A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528162A5 JP2018528162A5 JP2017568292A JP2017568292A JP2018528162A5 JP 2018528162 A5 JP2018528162 A5 JP 2018528162A5 JP 2017568292 A JP2017568292 A JP 2017568292A JP 2017568292 A JP2017568292 A JP 2017568292A JP 2018528162 A5 JP2018528162 A5 JP 2018528162A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- optionally substituted
- branched
- alkyl
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(C)(CSC(CC(N1CCNC(CCCSS[C@](C)(*)CCC(Nc2cc(COc(c(OC)c3)cc(NC[C@]4N5c6ccccc6C4)c3C5=O)cc(COc(cc(c(C(N(CC3)c4c3cccc4)=O)c3)N=*)c3OC)c2)=O)=O)=O)C1=O)C#C Chemical compound CC(C)(CSC(CC(N1CCNC(CCCSS[C@](C)(*)CCC(Nc2cc(COc(c(OC)c3)cc(NC[C@]4N5c6ccccc6C4)c3C5=O)cc(COc(cc(c(C(N(CC3)c4c3cccc4)=O)c3)N=*)c3OC)c2)=O)=O)=O)C1=O)C#C 0.000 description 8
- IWSKMCBAKLPXKV-UHFFFAOYSA-N CCC(CC(N1CCCC(NCC(NCC(NCC(NCCC(NCCN(C(CC2C)=O)C2=O)=O)=O)=O)=O)=O)=O)C1=O Chemical compound CCC(CC(N1CCCC(NCC(NCC(NCC(NCCC(NCCN(C(CC2C)=O)C2=O)=O)=O)=O)=O)=O)=O)C1=O IWSKMCBAKLPXKV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562186254P | 2015-06-29 | 2015-06-29 | |
| US62/186,254 | 2015-06-29 | ||
| US201662338245P | 2016-05-18 | 2016-05-18 | |
| US62/338,245 | 2016-05-18 | ||
| PCT/US2016/039796 WO2017004025A1 (en) | 2015-06-29 | 2016-06-28 | Conjugates of cysteine engineered antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021025322A Division JP2021088581A (ja) | 2015-06-29 | 2021-02-19 | システイン改変抗体の複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018528162A JP2018528162A (ja) | 2018-09-27 |
| JP2018528162A5 true JP2018528162A5 (enExample) | 2019-08-08 |
| JP6843080B2 JP6843080B2 (ja) | 2021-03-17 |
Family
ID=56409216
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568292A Active JP6843080B2 (ja) | 2015-06-29 | 2016-06-28 | システイン改変抗体の複合体 |
| JP2021025322A Pending JP2021088581A (ja) | 2015-06-29 | 2021-02-19 | システイン改変抗体の複合体 |
| JP2022129205A Active JP7441281B2 (ja) | 2015-06-29 | 2022-08-15 | システイン改変抗体の複合体 |
| JP2024021646A Pending JP2024067036A (ja) | 2015-06-29 | 2024-02-16 | システイン改変抗体の複合体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021025322A Pending JP2021088581A (ja) | 2015-06-29 | 2021-02-19 | システイン改変抗体の複合体 |
| JP2022129205A Active JP7441281B2 (ja) | 2015-06-29 | 2022-08-15 | システイン改変抗体の複合体 |
| JP2024021646A Pending JP2024067036A (ja) | 2015-06-29 | 2024-02-16 | システイン改変抗体の複合体 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10898579B2 (enExample) |
| EP (2) | EP3769787A1 (enExample) |
| JP (4) | JP6843080B2 (enExample) |
| KR (1) | KR102793098B1 (enExample) |
| CN (2) | CN107708810B (enExample) |
| AR (1) | AR106013A1 (enExample) |
| AU (2) | AU2016285929B2 (enExample) |
| CA (1) | CA2988806C (enExample) |
| CY (1) | CY1123606T1 (enExample) |
| DK (1) | DK3313845T3 (enExample) |
| ES (1) | ES2832527T3 (enExample) |
| HR (1) | HRP20201790T1 (enExample) |
| HU (1) | HUE052616T2 (enExample) |
| LT (1) | LT3313845T (enExample) |
| MA (1) | MA42250B1 (enExample) |
| MD (1) | MD3313845T2 (enExample) |
| PL (1) | PL3313845T3 (enExample) |
| PT (1) | PT3313845T (enExample) |
| RS (1) | RS61050B1 (enExample) |
| RU (1) | RU2733740C2 (enExample) |
| SI (1) | SI3313845T1 (enExample) |
| SM (1) | SMT202000614T1 (enExample) |
| TW (2) | TWI880021B (enExample) |
| WO (1) | WO2017004025A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017027254A2 (pt) | 2015-06-29 | 2019-05-14 | Immunogen, Inc. | anticorpos anti-cd123 e conjugados e derivados dos mesmos |
| WO2017091745A1 (en) | 2015-11-25 | 2017-06-01 | Immunogen, Inc. | Pharmaceutical formulations and methods of use thereof |
| WO2018098258A2 (en) | 2016-11-23 | 2018-05-31 | Immunogen, Inc. | Selective sulfonation of benzodiazepine derivatives |
| WO2018119196A1 (en) | 2016-12-23 | 2018-06-28 | Immunogen, Inc. | Immunoconjugates targeting adam9 and methods of use thereof |
| WO2018183494A1 (en) | 2017-03-31 | 2018-10-04 | Immunogen, Inc. | Cd19-targeting antibody-drug conjugates |
| CN111163804A (zh) * | 2017-09-22 | 2020-05-15 | 伊缪诺金公司 | 使用阳离子交换色谱法分离三轻链抗体 |
| MX2020003125A (es) | 2017-09-29 | 2020-10-01 | Daiichi Sankyo Co Ltd | Conjugado de anticuerpo-derivado de pirrolobenzodiazepina. |
| TWI897855B (zh) | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| JP7630435B2 (ja) | 2018-10-30 | 2025-02-17 | イミュノジェン， インコーポレイテッド | 抗ｃｄ１２３免疫複合体を用いた治療法 |
| MA54228A (fr) * | 2018-11-12 | 2021-09-22 | Immunogen Inc | Procédés de préparation de dérivés de benzodiazépine cytotoxiques |
| CN113166053A (zh) * | 2018-11-12 | 2021-07-23 | 伊缪诺金公司 | 制备细胞毒性苯二氮䓬衍生物的方法 |
| WO2020100954A1 (ja) | 2018-11-14 | 2020-05-22 | 第一三共株式会社 | 抗ｃｄｈ６抗体－ピロロベンゾジアゼピン誘導体コンジュゲート |
| JP2022527449A (ja) * | 2019-03-21 | 2022-06-02 | イミュノジェン・インコーポレーテッド | 細胞結合剤－薬物複合体の調製方法 |
| KR20210141630A (ko) | 2019-03-25 | 2021-11-23 | 다이이찌 산쿄 가부시키가이샤 | 항 her2 항체-피롤로벤조디아제핀 유도체 콘주게이트 |
| TWI856078B (zh) | 2019-03-25 | 2024-09-21 | 日商第一三共股份有限公司 | 抗體–吡咯并苯二氮呯衍生物結合物、其製造方法及其用途 |
| CA3139180A1 (en) | 2019-03-27 | 2020-10-01 | Daiichi Sankyo Company, Limited | Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor |
| SG11202110702WA (en) | 2019-04-29 | 2021-11-29 | Immunogen Inc | Therapeutic combinations comprising anti-cd123 immunoconjugates |
| CN116113641A (zh) | 2020-09-02 | 2023-05-12 | 第一三共株式会社 | 新型内－β－N－乙酰氨基葡萄糖苷酶 |
| KR20230146521A (ko) | 2021-01-13 | 2023-10-19 | 메모리얼 슬로안 케터링 캔서 센터 | 항체-피롤로벤조디아제핀 유도체 접합체 |
| IL312728A (en) | 2021-11-30 | 2024-07-01 | Daiichi Sankyo Co Ltd | Protease-cleavable masked antibodies |
| CA3251410A1 (en) | 2022-02-09 | 2025-07-08 | Daiichi Sankyo Co Ltd | Masked antibody sensitive to the environment and its use |
| WO2023167238A1 (ja) | 2022-03-02 | 2023-09-07 | 第一三共株式会社 | Ｆｃ含有分子の製造方法 |
| WO2025235924A2 (en) | 2024-05-10 | 2025-11-13 | Immunogen, Inc. | Anti-cd123 immunoconjugates for the treatment of acute myeloid leukemia |
| US20250345449A1 (en) | 2024-05-10 | 2025-11-13 | Immunogen, Inc. | Anti-cd123 immunoconjugates for the treatment of blastic plasmacytoid cell neoplasm |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2076465C (en) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
| GB9422383D0 (en) * | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
| DK1242401T3 (da) | 1999-11-24 | 2007-05-07 | Immunogen Inc | Cytotoksiske midler, der omfatter taxaner, og den terapeutiske anvendelse deraf |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
| WO2004013093A2 (en) | 2002-08-02 | 2004-02-12 | Immunogen, Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
| ATE499116T1 (de) | 2002-08-16 | 2011-03-15 | Immunogen Inc | Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln |
| CN1795009B (zh) | 2002-11-07 | 2014-07-09 | 伊谬诺金公司 | 抗-cd33抗体及其用途 |
| CN101239190B (zh) * | 2003-01-27 | 2013-09-25 | 恩多塞特公司 | 维生素受体结合递药缀合物 |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| ES2533695T3 (es) | 2004-03-02 | 2015-04-14 | Seattle Genetics, Inc. | Anticuerpos cargados parcialmente y métodos para su conjugación |
| BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
| BRPI0516284A (pt) | 2004-09-23 | 2008-09-02 | Genentech Inc | anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto |
| WO2006065533A2 (en) | 2004-11-29 | 2006-06-22 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| AR060978A1 (es) | 2006-05-30 | 2008-07-23 | Genentech Inc | Anticuerpos e inmunoconjugados y sus usos |
| EP2139924B1 (en) | 2007-03-29 | 2016-07-06 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| US8236319B2 (en) | 2008-04-30 | 2012-08-07 | Immunogen, Inc. | Cross-linkers and their uses |
| MX2010011808A (es) | 2008-04-30 | 2011-03-04 | Immunogen Inc | Conjugados potentes y enlazadores hidrofilicos. |
| CN105198908B (zh) * | 2009-02-05 | 2019-12-24 | 伊缪诺金公司 | 新型苯并二氮杂*衍生物 |
| US8431416B2 (en) * | 2009-04-01 | 2013-04-30 | Becton, Dickinson And Company | Reactive heterocycle-substituted 7-hydroxycoumarins and their conjugates |
| AU2010270979B2 (en) | 2009-06-22 | 2015-04-23 | Medimmune, Llc | Engineered Fc regions for site-specific conjugation |
| WO2011092838A1 (ja) | 2010-01-29 | 2011-08-04 | 株式会社フォーサイド・ドット・コム | コンテンツ共有システム、およびコンテンツ共有方法 |
| KR20170085143A (ko) * | 2010-02-24 | 2017-07-21 | 이뮤노젠 아이엔씨 | 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도 |
| HUE046360T2 (hu) | 2010-03-12 | 2020-03-30 | Debiopharm Int Sa | CD37-kötõ molekulák és azok immunkonjugátumai |
| HUE068268T2 (hu) | 2010-04-20 | 2024-12-28 | Genmab As | Heterodimer antitest Fc-t tartalmazó fehérjék és azok elõállítási eljárásai |
| EP2632947A4 (en) | 2010-10-29 | 2015-03-18 | Immunogen Inc | NON-ANTAGONIST MOLECULES BINDING TO THE EGF RECEPTOR AND IMMUNOCONJUGATES THEREOF |
| SG189929A1 (en) | 2010-10-29 | 2013-06-28 | Immunogen Inc | Novel egfr-binding molecules and immunoconjugates thereof |
| PT2675480T (pt) * | 2011-02-15 | 2019-04-15 | Immunogen Inc | Métodos para preparação de conjugados |
| WO2013177481A1 (en) * | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
| WO2014134457A2 (en) | 2013-02-28 | 2014-09-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| EP2961434A2 (en) | 2013-02-28 | 2016-01-06 | ImmunoGen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| US9901647B2 (en) | 2013-02-28 | 2018-02-27 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| ES2719584T3 (es) * | 2014-04-11 | 2019-07-11 | Medimmune Llc | Compuestos conjugados que comprenden anticuerpos modificados por ingeniería genética con cisteína |
| AU2015276821A1 (en) * | 2014-06-20 | 2017-01-12 | Abgenomics International Inc. | Anti-folate receptor aplha (FRA) antibody-drug conjugates and methods of using thereof |
| AR100919A1 (es) * | 2014-06-20 | 2016-11-09 | Bioalliance Cv | Conjugados de fármaco-anticuerpo anti-cd22 y métodos de uso de los mismos |
| SG10201811124YA (en) * | 2014-06-20 | 2019-01-30 | Abgenomics Int Inc | Her2 antibody-drug conjugates |
| JP2017526682A (ja) | 2014-09-02 | 2017-09-14 | イミュノジェン， インコーポレイテッド | 抗体薬物複合体組成物の製剤化方法 |
| MA41645A (fr) | 2015-03-04 | 2018-01-09 | Abbvie Stemcentrx Llc | Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation |
| BR112017027254A2 (pt) | 2015-06-29 | 2019-05-14 | Immunogen, Inc. | anticorpos anti-cd123 e conjugados e derivados dos mesmos |
| WO2018098258A2 (en) * | 2016-11-23 | 2018-05-31 | Immunogen, Inc. | Selective sulfonation of benzodiazepine derivatives |
-
2016
- 2016-06-28 LT LTEP16738322.3T patent/LT3313845T/lt unknown
- 2016-06-28 ES ES16738322T patent/ES2832527T3/es active Active
- 2016-06-28 WO PCT/US2016/039796 patent/WO2017004025A1/en not_active Ceased
- 2016-06-28 EP EP20182141.0A patent/EP3769787A1/en active Pending
- 2016-06-28 SI SI201630977T patent/SI3313845T1/sl unknown
- 2016-06-28 CN CN201680038492.0A patent/CN107708810B/zh active Active
- 2016-06-28 KR KR1020187002729A patent/KR102793098B1/ko active Active
- 2016-06-28 RU RU2017144859A patent/RU2733740C2/ru active
- 2016-06-28 PL PL16738322T patent/PL3313845T3/pl unknown
- 2016-06-28 AU AU2016285929A patent/AU2016285929B2/en active Active
- 2016-06-28 JP JP2017568292A patent/JP6843080B2/ja active Active
- 2016-06-28 DK DK16738322.3T patent/DK3313845T3/da active
- 2016-06-28 HR HRP20201790TT patent/HRP20201790T1/hr unknown
- 2016-06-28 MD MDE20180452T patent/MD3313845T2/ro unknown
- 2016-06-28 CN CN202111168673.4A patent/CN113769108B/zh active Active
- 2016-06-28 CA CA2988806A patent/CA2988806C/en active Active
- 2016-06-28 US US15/195,269 patent/US10898579B2/en active Active
- 2016-06-28 SM SM20200614T patent/SMT202000614T1/it unknown
- 2016-06-28 PT PT167383223T patent/PT3313845T/pt unknown
- 2016-06-28 MA MA42250A patent/MA42250B1/fr unknown
- 2016-06-28 HU HUE16738322A patent/HUE052616T2/hu unknown
- 2016-06-28 EP EP16738322.3A patent/EP3313845B1/en active Active
- 2016-06-28 RS RS20201354A patent/RS61050B1/sr unknown
- 2016-06-29 TW TW110132303A patent/TWI880021B/zh active
- 2016-06-29 TW TW105120514A patent/TWI740833B/zh active
- 2016-06-29 AR ARP160101972A patent/AR106013A1/es active IP Right Grant
-
2020
- 2020-09-08 US US17/014,404 patent/US20210085800A1/en not_active Abandoned
- 2020-11-10 CY CY20201101058T patent/CY1123606T1/el unknown
-
2021
- 2021-02-19 JP JP2021025322A patent/JP2021088581A/ja active Pending
-
2022
- 2022-03-31 AU AU2022202208A patent/AU2022202208B2/en active Active
- 2022-08-15 JP JP2022129205A patent/JP7441281B2/ja active Active
-
2024
- 2024-02-16 JP JP2024021646A patent/JP2024067036A/ja active Pending
- 2024-06-11 US US18/739,709 patent/US20250011340A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018528162A5 (enExample) | ||
| RU2017144859A (ru) | Конъюгаты сконструированных антител с цистеиновыми заменами | |
| CN119306732B (zh) | 生物活性物偶联物及其制备方法和用途 | |
| EP2968593B1 (en) | Biologically active molecules, conjugates thereof, and therapeutic uses | |
| EP3327027B1 (en) | Cytotoxic peptides and antibody drug conjugates thereof | |
| JP2017529837A5 (enExample) | ||
| AU2022204711B9 (en) | Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation | |
| EP2790731A2 (de) | Fgfr-binder-wirkstoff konjugate und ihre verwendung | |
| EP3501546A2 (de) | Cystein-wirkstoff konjugate und ihre verwendung | |
| US20090105200A1 (en) | Combination therapy | |
| EP3408271A1 (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| AU2018368520B2 (en) | Ligand-drug-conjugates as substrates for selective cleavage by the exopeptidase activity of Cathepsin B | |
| JP2018016629A (ja) | 固形腫瘍を治療するためのｆａｐ活性化プロテアソーム阻害剤 | |
| JP2018528261A (ja) | グルタミン類似体のプロドラッグ | |
| CA3003085A1 (en) | Cryptophycin compounds and conjugates, their preparation and their therapeutic use | |
| US20010056178A1 (en) | Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them | |
| JP2016510730A5 (enExample) | ||
| TW202515620A (zh) | 抗體－藥物偶聯物靶向治療前列腺癌和其他腫瘤 | |
| KR20250163875A (ko) | 핵 위치화 폴리펩타이드 및 컨주게이트 및 이의 용도 | |
| WO2024206118A1 (en) | Nuclear localization polypeptides and conjugates and uses thereof | |
| HK40085405A (en) | Method for producing antibody-drug conjugate | |
| EA045708B1 (ru) | Новые пептидные линкеры и конъюгаты на основе криптофицина, их получение и их терапевтическое применение | |
| EA046139B1 (ru) | Конъюгаты лиганда-лекарственного средства в качестве субстратов для селективного расщепления под действием экзопептидазной активности катепсина b | |
| HK1212890B (en) | Biologically active molecules, conjugates thereof, and therapeutic uses | |
| HK40066743A (en) | Biologically active molecules, conjugates thereof, and therapeutic uses |